Wednesday, September 27, 2017 4:19:08 PM
Thank you for your email. We presented a company update today at the Cantor conference: http://ir.genocea.com/events.cfm
Regarding the decision to explore strategic alternatives for GEN-003, we have been in the process of seeking capital to secure financing for GEN-003 for some time now and previously announced that, if we were not able to secure such capital, we would be reviewing our strategic alternatives to maximize value.
Since the time of those disclosures, we have determined that the significant financial resources required to advance GEN-003 into a large and long Phase 3 program are beyond Genocea alone, as such we are reviewing strategic alternatives for GEN-003 as we seek the right partner to move the program forward.
Given this reality, we have had to make the hard decision to restructure our workforce and to focus on our cancer work, which leverages our core ATLAS platform technology as a potentially superior approach to neoantigen selection for next generation cancer vaccines.
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM